Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23343522 | 1.00 | NR1D1 (0.50) | NR1D1NOTUMTP53 | |
| SCHEMBL433888 | 0.86 | MTNR1A (0.54) | NR1D1NOTUM | |
| SCHEMBL23182808 | 0.85 | NPC1 (0.48) | — | |
| SCHEMBL13068180 | 0.84 | NR1D1 (0.49) | NR1D1NOTUMTP53 | |
| SCHEMBL17461323 | 0.84 | NR1D1 (0.49) | NR1D1NOTUMTP53 | |
| SCHEMBL11389554 | 0.84 | NR1D1 (0.49) | NR1D1NOTUMTP53 | |
| SCHEMBL5847274 | 0.83 | DRD2 (0.48) | NOTUM | |
| SCHEMBL5847272 | 0.83 | DRD2 (0.48) | NOTUM | |
| SCHEMBL5847276 | 0.83 | DRD2 (0.48) | NOTUM | |
| SCHEMBL10743464 | 0.83 | DRD2 (0.49) | NR1D1NOTUMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3258925-B1 | METHODS AND COMPOSITIONS FOR DECREASING GASTRIC EMPTYING | PURDUE PHARMA LP (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-3097078-B1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3209497-B1 | QUATERNARY PHOSPHONIUM COATED SURFACES AND METHODS OF MAKING THE SAME | ORTHOBOND INC (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3083606-B1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3666274-A1 | CARBOXAMIDE DERIVATIVES AND USE THEREOF | Purdue Pharma LP (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3087059-B1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3039019-B1 | AZASPIRO[4.5]DECANE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3105217-B1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180134832-A1 | QUATERNARY PHOSPHONIUM COATED SURFACES AND METHODS OF MAKING THE SAME | ORTHOBOND INC (US) | 2018-05-17 | — | — | US | disclosed |
| US-8829006-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2014096941-A1 | CYCLIC SULFONAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013072758-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| EP-1608377-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARM INC (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| US-5017584-A | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas | STERLING DRUG INC. (US) | 1991-05-21 | — | — | US | disclosed |
| US-4598086-A | ANTIDERPRESSANTS; HYPERTENSIVE AGENTS | SYNTHELABO, (FR) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | NR1D1 1648/4885NOTUM 3225/4885TP53 4503/4885 |
| US-20120149698-A1 | NOUVEL COMPOUNDS | BDKRB2, CALCR, CALCRL | NR1D1 801/4885NOTUM 573/4885TP53 2769/4885 |
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | NR1D1 504/4885NOTUM 3226/4885TP53 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.